Medication evidence profile
Cinnarizine
Clinical overview
Cinnarizine has public medication-list entries in Swe-ABS 2023, KABS 2020 open validation supplement, and CALS 2022 Table 4. These are 3 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | Not listed |
| Yamada-ABS | Not listed |
| BAAS | Not listed |
| Swe-ABS | 1 |
| GABS | Not listed |
| KABS | 1 |
| CALS | 1 |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
How to interpret the evidence
3 of 7 public source versions contain an explicit medication-list entry for cinnarizine.
The available rows for cinnarizine display the same numeric value. Agreement of the displayed numbers does not establish identical methods, clinical meaning or patient-level risk.
None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.
Source labels and provenance · 3 observations
- Swedish Anticholinergic Burden Scale 2023
Source label: Cinnarizine. Published value: 1.
Source version: SWE-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_final_nonzero_complete
Observation: SWE_ABS_2023_R0012; rating state: published_rating. - KABS 2019 scale - 2020 open validation supplement
Source label: Cinnarizine. Published value: 1.
Source version: KABS-2020-validation-supplement
Source location: Additional file 1; category Antivertigo preparations; table row 50
Observation: KABS2020_SUPP_0201; rating state: published_validation_supplement_rating. - CALS 2022 - primary final Table 4
Source label: Cinnarizine. Published value: 1.
Source version: CALS-2022-primary-table4
Source location: Table 4; literal capture row 155; displayed table row 23; displayed column 1
Observation: CALS2022_T4_0155; rating state: published_final_table_rating.
What this page does not establish
- No medication-list entry is available here from JARS 2025, Yamada-ABS 2023, BAAS 2019, and GABS 2018. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- No route inference unless present in the source label.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
- Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source
- Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic Load Scale: an updated anticholinergic burden scale. Comparison with the ACB Scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. doi:10.3390/jpm12020207. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Cinnarizine
Ask about this medication